130 related articles for article (PubMed ID: 20531064)
1. Prevalence of acute vasoresponsiveness in patients with pulmonary hypertension: treatment implications.
Arunthari V; Heckman MG; Burger CD
South Med J; 2010 Jul; 103(7):630-4. PubMed ID: 20531064
[TBL] [Abstract][Full Text] [Related]
2. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
Sitbon O; Humbert M; Jaïs X; Ioos V; Hamid AM; Provencher S; Garcia G; Parent F; Hervé P; Simonneau G
Circulation; 2005 Jun; 111(23):3105-11. PubMed ID: 15939821
[TBL] [Abstract][Full Text] [Related]
3. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.
Milman N; Svendsen CB; Iversen M; Videbaek R; Carlsen J
Clin Respir J; 2009 Oct; 3(4):207-13. PubMed ID: 20298406
[TBL] [Abstract][Full Text] [Related]
4. Role of Vasodilator Testing in Pulmonary Hypertension.
Sharma A; Obiagwu C; Mezue K; Garg A; Mukherjee D; Haythe J; Shetty V; Einstein AJ
Prog Cardiovasc Dis; 2016; 58(4):425-33. PubMed ID: 26434988
[TBL] [Abstract][Full Text] [Related]
5. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.
Preston IR; Klinger JR; Landzberg MJ; Houtchens J; Nelson D; Hill NS
Chest; 2001 Sep; 120(3):866-72. PubMed ID: 11555522
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.
Tonelli AR; Alnuaimat H; Mubarak K
Respir Med; 2010 Apr; 104(4):481-96. PubMed ID: 20004088
[TBL] [Abstract][Full Text] [Related]
7. Comparison between two drugs on the hemodynamic evaluation of pulmonary hypertension prior to heart transplantation.
Mogollón Jiménez MV; Escoresca Ortega AM; Hinojosa Pérez R; Lage Gallé E; Herruzo Avilés A; Sobrino Márquez M; Frutos López M; Romero Rodríguez N; Pérez de la Yglesia R; Martínez Martínez A
Transplant Proc; 2008 Nov; 40(9):3009-11. PubMed ID: 19010174
[TBL] [Abstract][Full Text] [Related]
8. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.
Sitbon O; Brenot F; Denjean A; Bergeron A; Parent F; Azarian R; Herve P; Raffestin B; Simonneau G
Am J Respir Crit Care Med; 1995 Feb; 151(2 Pt 1):384-9. PubMed ID: 7842196
[TBL] [Abstract][Full Text] [Related]
9. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.
Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS
Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.
Halliday SJ; Hemnes AR; Robbins IM; Pugh ME; Zhao DX; Piana RN; Fong PP; Brittain EL
J Heart Lung Transplant; 2015 Mar; 34(3):312-8. PubMed ID: 25577565
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
12. Acute absolute vasodilatation is associated with a lower vascular wall stiffness in pulmonary arterial hypertension.
Grignola JC; Domingo E; Aguilar R; Vázquez M; López-Messeguer M; Bravo C; Roman A
Int J Cardiol; 2013 Apr; 164(2):227-31. PubMed ID: 21788089
[TBL] [Abstract][Full Text] [Related]
13. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.
Buckley MS; Feldman JP
Pharmacotherapy; 2010 Jul; 30(7):728-40. PubMed ID: 20575636
[TBL] [Abstract][Full Text] [Related]
14. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties.
Ulrich S; Fischler M; Speich R; Popov V; Maggiorini M
Chest; 2006 Sep; 130(3):841-6. PubMed ID: 16963684
[TBL] [Abstract][Full Text] [Related]
15. Differences in the acute pulmonary vascular effects of oxygen with nitric oxide and diltiazem: implications for the long-term treatment of pulmonary arterial hypertension.
Day RW
Congenit Heart Dis; 2013; 8(1):71-7. PubMed ID: 22891699
[TBL] [Abstract][Full Text] [Related]
16. Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria.
Costa EL; Jardim C; Bogossian HB; Amato MB; Carvalho CR; Souza R
Vascul Pharmacol; 2005 Sep; 43(3):143-7. PubMed ID: 16061423
[TBL] [Abstract][Full Text] [Related]
17. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
18. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers.
Zuo XR; Zhang R; Jiang X; Li XL; Zong F; Xie WP; Wang H; Jing ZC
Am J Cardiol; 2012 Jun; 109(12):1801-6. PubMed ID: 22459309
[TBL] [Abstract][Full Text] [Related]
20. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.
Bhatia S; Frantz RP; Severson CJ; Durst LA; McGoon MD
Mayo Clin Proc; 2003 Oct; 78(10):1207-13. PubMed ID: 14531479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
